roxadustat + Darbepoetin alfa

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hemodialysis Chronic Kidney Disease Patients With Anemia

Conditions

Hemodialysis Chronic Kidney Disease Patients With Anemia

Trial Timeline

Nov 30, 2016 → Mar 15, 2018

NCT ID

NCT02952092

About roxadustat + Darbepoetin alfa

roxadustat + Darbepoetin alfa is a phase 3 stage product being developed by Astellas Pharma for Hemodialysis Chronic Kidney Disease Patients With Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02952092. Target conditions include Hemodialysis Chronic Kidney Disease Patients With Anemia.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis Chronic Kidney Disease Patients With Anemia were approved

Approved (2) Terminated (0) Active (13)

🔄R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3

🔄R744 + R744Chugai PharmaceuticalPhase 3

🔄R744Chugai PharmaceuticalPhase 3

🔄roxadustatAstellas PharmaPhase 3

✅DoravirineMerckApproved

🔄PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02952092	Phase 3	Completed	Nov 30, 2016	Mar 15, 2018	Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02021318	Phase 3	Completed	Mar 12, 2014	Nov 6, 2019	Anemia in Chronic Kidney Disease in Non-dialysis Patients
NCT01888445	Phase 2	Completed	Mar 28, 2013	Sep 15, 2014	Renal Anemia Associated With Chronic Renal Failure (CRF)

Competing Products

20 competing products in Hemodialysis Chronic Kidney Disease Patients With Anemia

See all competitors

Product	Company	Stage	Hype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo	Chugai Pharmaceutical	Phase 3	40
R744 + R744	Chugai Pharmaceutical	Phase 3	40
R744	Chugai Pharmaceutical	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
ASP7991	Astellas Pharma	Phase 1	29
roxadustat	Astellas Pharma	Phase 3	40
ASP1585	Astellas Pharma	Phase 2	35
Kiklin capsules	Astellas Pharma	Pre-clinical	26
Doravirine	Merck	Approved	43
BPS804 + Placebo	Novartis	Phase 2	27
PA21 + Sevelamer hydrochloride	Kissei Pharmaceutical	Phase 3	40
PA21 + PA21 + PA21 + PA21 + Placebo	Kissei Pharmaceutical	Phase 2	35
PA21	Kissei Pharmaceutical	Phase 3	40
PA21	Kissei Pharmaceutical	Phase 3	40
[¹⁴C]Etelcalcetide	Amgen	Phase 1	29
Epoetin Hospira	Pfizer	Phase 3	40
Epoetin Hospira	Pfizer	Phase 3	40
sodium thiosulfate	Sanofi	Pre-clinical	26
Enoxaparine	Sanofi	Approved	43
Alirocumab 150 MG/ML [Praluent]	Regeneron Pharmaceuticals	Phase 3	36